$82.11
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Country

US

CEO

Mr. Nikhil Lalwani

IPO date

2000

Employees

970

ISIN

US00182C1036

Key stats

Open

$81.68

Volume

179.77K

Market cap

$1.86B

Prev. close

$81.68

Impl / hst vl

-

Open interest

$0.00

$81.25

Day’s Range

$82.99

$70.15

52W Range

$87.76

Valuation

72
Valuation score
Undervalued
P/E
18.99
P/S
1.89
P/B
3.11
Current ratio
3.12
Debt / Equity
0.54
ROE
17.80%
Gross margin
60.59%
Income growth
8.04%
FCF growth
79.59

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$111.33
The top 10 analysts forecasts that 12-month price may increase by 35.58%, with a low of $90.90 and a high of $130.20
$90.90
Low
$111.33
Avg
$130.20
High
Current price

Earnings

Q1 ‘26 revenue
$237.46M
Q1 ‘26 net income
$27.43M
Revenue
Net income
Previous EPS
$2.33
Estimate EPS
$1.33
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply